USPTO Art Unit 1651 Prosecution Statistics

Art Unit Information

Art Unit: 1651
Group: 1650
Tech Center: 1600
Total Cases: 14,177
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19005540PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLEDecember 2024June 2025Allow510NoNo
18934153FILAMENTOUS FUNGUS AND USE THEREOF IN GAS METABOLISMOctober 2024April 2025Allow510NoNo
18894673SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSSeptember 2024June 2025Abandon801NoNo
18885661POLYMERASE MUTANT AND APPLICATIONS THEREOFSeptember 2024February 2025Allow510YesNo
18820753BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITISAugust 2024January 2025Allow510NoNo
18739955SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSJune 2024January 2025Allow710NoNo
18656340HUMAN ALPHA-GALACTOSIDASE VARIANTSMay 2024November 2024Allow600YesNo
18654723PROCESS FOR PRODUCTION OF A SOLUBLE AND INSOLUBLE COLLAGEN PRODUCT FROM MAMMALIAN DERMIS TISSUEMay 2024August 2024Allow411YesNo
18637707METHODS FOR QUANTIFYING FRATAXIN ACTIVITYApril 2024May 2025Allow1310YesNo
18634776OLIGOSACCHARIDE DEBRANCHING ENZYME MUTANT AND USE THEREOF IN GLUCOSE MOTHER LIQUORApril 2024April 2025Allow1200YesNo
18632871FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USEApril 2024April 2025Allow1220NoNo
18631959BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITISApril 2024August 2024Allow410NoNo
18628247Distributed Systems for the Efficient Production and Use of Microbe-Based CompositionsApril 2024March 2025Allow1111NoNo
18626855SYSTEMS AND METHODS FOR GROWTH OF INTESTINAL CELLS IN MICROFLUIDIC DEVICESApril 2024March 2025Allow1100NoNo
18627241SPORE-BASED PROBIOTIC SUPPLEMENTATION IN DOGS AND CONTROL OF ENDOTOXEMIAApril 2024April 2025Allow1210NoNo
18615574FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USEMarch 2024September 2024Allow610YesNo
18597734Non-Toxic Pest Control Compositions and Methods and Uses ThereofMarch 2024February 2025Allow1210YesNo
18594570EDIBLE PLANT PARTS ENRICHED WITH PROBIOTIC BACTERIAMarch 2024June 2025Allow1510YesNo
18591288METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICSFebruary 2024April 2025Abandon1310NoNo
18588987SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2024September 2024Allow710YesNo
18588956SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2024October 2024Abandon801NoNo
18588930SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2024September 2024Allow710YesNo
18587665Methods of Adding Polymers to Ribonucleic AcidsFebruary 2024February 2025Allow1201YesNo
18581700ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USEFebruary 2024January 2025Allow1100YesNo
18440808METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOMEFebruary 2024January 2025Allow1121YesNo
18682024METHOD FOR PRODUCING A RECOMBINANT BACTERIAL COLLAGEN-LIKE PROTEIN (CLP)February 2024September 2024Allow710YesNo
18432324ANTIMICROBIAL HEVAMINE A-RELATED COMPOSITIONS AND METHODSFebruary 2024December 2024Allow1011YesNo
18511300APPLICATION OF BACILLUS COAGULANS IN PREPARING MEDICATION FOR IMPROVING FUNCTIONAL DECLINE OF ORGANISMS CAUSED BY HYPERGLYCEMIA AND HYPERLIPIDEMIAJanuary 2024April 2025Abandon1710NoNo
18424277ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOMEJanuary 2024June 2025Abandon1711NoNo
18421847SUSPENSION CULTURE OF HUMAN EMBRYONIC STEM CELLSJanuary 2024June 2025Allow1730YesNo
18417268Anaerobic Blood Storage and Pathogen Inactivation MethodJanuary 2024March 2025Allow1410NoNo
18417981METHODS OF PROCESSING MUNICIPAL SOLID WASTE (MSW) USING MICROBIAL HYDROLYSIS AND FERMENTATIONJanuary 2024April 2025Abandon1501NoNo
18411888MULTIUSE, ENZYMATIC DETERGENT AND METHODS OF STABILIZING A USE SOLUTIONJanuary 2024November 2024Allow1010YesNo
18409148METHOD FOR QUANTIFYING AT LEAST ONE MICROORGANISM GROUP VIA MASS SPECTROMETRYJanuary 2024June 2025Allow1711NoNo
18407334DETERGENT COMPOSITIONS COMPRISING BACTERIAL MANNANASESJanuary 2024June 2025Allow1710NoNo
18406008TREATMENT OF VON WILLEBRAND DISEASEJanuary 2024January 2025Allow1210NoNo
18394616RUMINANT COMPOSITIONSDecember 2023April 2025Abandon1610NoNo
18391409PDE5A DESTABILIZING DOMAINSDecember 2023April 2025Abandon1510NoNo
18544083BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITISDecember 2023April 2024Allow410NoNo
18544275FUSION CONSTRUCTS AS PROTEIN OVER-EXPRESSION VECTORSDecember 2023April 2025Allow1610YesNo
18540631PROCESS FOR PRODUCTION OF SUGAR FROM A COTTON-CONTAINING TEXTILEDecember 2023March 2025Abandon1511NoNo
18534962MICROBIOME PROTECTION FROM ORAL ANTIBIOTICSDecember 2023December 2024Allow1210NoNo
18535652GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOFDecember 2023June 2025Allow1810NoNo
18568959A METHOD OF CELL LYSISDecember 2023May 2025Allow1710YesNo
18530082ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATESDecember 2023April 2025Allow1611YesNo
18526930COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTIONDecember 2023April 2025Allow1611YesNo
18519620POLYMERASE ENZYME FROM 9�NNovember 2023March 2025Abandon1610NoNo
18515559Pharmaceutical Composition of a Recombinant Adeno-Associated Virus Vector and its ApplicationNovember 2023May 2025Allow1832NoNo
18505438METHODS AND SYSTEMS FOR THE CULTURE OF CELLS AT LIQUID-LIQUID INTERFACESNovember 2023June 2025Abandon1901NoNo
18387563BIOLOGICAL-SPECIMEN TRANSPARENTIZING AGENT, SYSTEM, AND USE THEREFORNovember 2023March 2025Abandon1610NoNo
18498391COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILISOctober 2023February 2025Allow1610NoNo
18498455COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILISOctober 2023March 2025Allow1610NoNo
18493395ATTENUATED GLUTAMINE SYNTHETASE AS A SELECTION MARKEROctober 2023January 2025Abandon1401NoNo
18492533NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHEOctober 2023January 2025Abandon1510NoNo
18490629PROBIOTIC COMPOSITIONOctober 2023April 2025Allow1820NoNo
18490521COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILISOctober 2023February 2025Allow1610NoNo
18381795COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKINOctober 2023July 2025Abandon2011NoNo
18381418CELLULAR COMPOSITIONS DERIVED FROM PRIOR ORGAN DONORS AND METHODS OF MANUFACTURE AND USE THEREOFOctober 2023April 2025Abandon1801NoNo
18380292METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSISOctober 2023March 2025Abandon1701NoNo
18286782PROCESS TO PRODUCE MONO-RHAMNOLIPIDSOctober 2023March 2025Allow1740YesNo
18485872COMPOSITIONS AND METHODS FOR C. DIFFICILE TREATMENTOctober 2023August 2024Allow1010NoNo
18378133TWO-STAGE PROCESS FOR PRODUCING OIL FROM MICROALGAEOctober 2023June 2025Abandon2010NoNo
18478368COLLAGENASE FORMULATIONS AND METHODS OF PRODUCING THE SAMESeptember 2023January 2025Allow1620NoNo
18476483METHODS AND COMPOSITIONS FOR PRESERVING BACTERIASeptember 2023July 2025Allow2120YesNo
18471478ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTIONSeptember 2023February 2025Allow1710NoNo
18464379METHOD AND SYSTEMS FOR ISOLATION AND/OR SEPARATION OF PRODUCTS FROM PRODUCTION PROCESSESSeptember 2023May 2025Allow2030YesNo
18461604OLIGOPEPTIDE WITH LIPID-LOWERING ACTIVITY, PREPARATION METHOD AND APPLICATION THEREOFSeptember 2023June 2024Allow1010YesNo
18462237ENGINEERED AMYLASE VARIANTSSeptember 2023April 2024Allow700YesNo
18460092Papermaking Additive Compositions and Methods and Uses ThereofSeptember 2023December 2024Allow1510YesNo
18460129Non-Toxic Plant Agent Compositions and Methods and Uses ThereofSeptember 2023March 2025Allow1810YesNo
18460056Liquid Bio-Catalytic CompositionSeptember 2023March 2025Allow1810YesNo
18460124BACILLUS COAGULANS FOR IMPROVING CONSTIPATION AND APPLICATION THEREOFSeptember 2023November 2024Abandon1520NoNo
18458388PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USEAugust 2023January 2025Allow1710NoNo
18455342METHODS FOR OPTIMIZING GAS UTILIZATIONAugust 2023May 2025Abandon2010NoNo
18454562COMPOSITION FOR PROMOTING THE GROWTH OF LACTIC ACID BACTERIA COMPRISING GROWTH FACTORSAugust 2023October 2024Allow1410NoNo
18448856RNA POLYMERASE VARIANTSAugust 2023August 2024Allow1201YesNo
18447387DISTRIBUTED SYSTEMS FOR THE EFFICIENT PRODUCTION AND USE OF MICROBE-BASED COMPOSITIONSAugust 2023December 2023Allow410NoNo
18446758CARBON SEQUESTRATION IN SOILS WITH PRODUCTION OF CHEMICAL PRODUCTSAugust 2023September 2024Allow1311YesNo
18446136CULTURE MEDIUM COMPOSITIONAugust 2023December 2024Abandon1610NoNo
18230923COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASESAugust 2023May 2025Allow2110NoNo
18360627CRYOPRESERVING UNGULATE EMBRYOSJuly 2023June 2025Abandon2320NoNo
18226833Method for Modifying Polyester by Swelling Agent Combined with CutinaseJuly 2023January 2024Allow610YesNo
18226559PROTEINASE-FREE COATINGS FOR COLONY PASSAGINGJuly 2023August 2024Allow1310NoNo
18354044METHODS FOR CO-PRODUCING ERYTHRITOL AND ARABINOSE BY USING XYLOSE MOTHER LIQUORJuly 2023October 2023Allow200NoNo
18222943METHOD OF INHIBITING MYCOTOXIN GROWTH USING ARTHROSPIRA PLATENSIS NANOPARTICLESJuly 2023October 2023Allow310YesNo
18351961NOVEL BACTERIOPHAGE THAT LYSES ACINETOBACTER GENUS BACTERIA HAVING RESISTANCE TO ANTIBIOTICSJuly 2023September 2024Abandon1401NoNo
18220975METHODS OF RECOVERING OIL FROM MICROORGANISMSJuly 2023February 2025Allow1910NoNo
18350559AGRICULTURALLY BENEFICIAL MICROBES, MICROBIAL COMPOSITIONS, AND CONSORTIAJuly 2023October 2024Abandon1510NoNo
18219581SYNBIOTIC COMPOSITION FOR IMPROVING IMMUNE RESPONSE AND ANTIOXIDANT CAPACITY DURING AGING AND A PROCESS FOR THE PREPARATION THEREOFJuly 2023November 2024Allow1620YesNo
18270925COMPOSITION COMPRISING THREE LACTOBACILLUS SP. STRAINS, AND USE THEREOFJuly 2023March 2025Allow2030YesNo
18217743COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN-RELATED DISEASES AND PROMOTING DERMATOLOGICAL HEALTHJuly 2023June 2025Allow2320NoNo
18343514BONE MARROW MICROFLUIDIC DEVICES AND METHODS FOR PREPARING AND USING THE SAMEJune 2023August 2024Allow1410NoNo
18214335EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASEJune 2023January 2025Allow1921NoNo
18213528Compositions and Methods for Cleaning Contaminated Solids and LiquidsJune 2023August 2024Allow1310NoNo
18338437Quality Assurance of ChondrocytesJune 2023November 2024Allow1710NoNo
18337292STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETOJune 2023March 2025Allow2111NoNo
18336973APPLICATION OF MEDICAL CELL CMU-PB-7 IN PREPARATION OF BLOOD LIPID-LOWERING DRUGSJune 2023February 2024Allow820NoNo
18210901MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATESJune 2023April 2025Allow2220YesNo
18267874ALLULOSE EPIMERASE VARIANT WITH EXCELLENT THERMAL STABILITY, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR ALLULOSE USING SAMEJune 2023October 2024Allow1600NoNo
18210234ALGAE-BASED BIOPLASTICS AND METHODS OF MAKINGJune 2023October 2024Allow1710YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1651.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
241
Examiner Affirmed
166
(68.9%)
Examiner Reversed
75
(31.1%)
Reversal Percentile
44.4%
Lower than average

What This Means

With a 31.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1335
Allowed After Appeal Filing
299
(22.4%)
Not Allowed After Appeal Filing
1036
(77.6%)
Filing Benefit Percentile
9.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1651 - Prosecution Statistics Summary

Executive Summary

Art Unit 1651 is part of Group 1650 in Technology Center 1600. This art unit has examined 14,177 patent applications in our dataset, with an overall allowance rate of 53.5%. Applications typically reach final disposition in approximately 35 months.

Comparative Analysis

Art Unit 1651's allowance rate of 53.5% places it in the 9% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1651 receive an average of 2.02 office actions before reaching final disposition (in the 67% percentile). The median prosecution time is 35 months (in the 19% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.